Systemic therapy for the treatment of metastatic kidney cancer brain metastases

Research published in Clinical Genitourinary Cancer this month looked at the use of systemic therapy for the treatment of patients with spread of metastatic renal cell carcinoma (RCC) to the brain (brain metastases). In recent years, the use of modern radiotherapy has resulted in significant improvements in the control and overall survival of RCC that has […]

read more

Clinical impact of COVID-19 on people with cancer

A recent publication in The Lancet looked at the effect of COVID-19 on the treatment of people with cancer. Data from cancer patients living in the USA, Canada and Spain who were infected with coronavirus were analysed. Nine hundred and twenty eight (928) people with an active or previous cancer and confirmed severe acute respiratory […]

read more

ASCO 2019: Active surveillance in metastatic kidney cancer

This study used data from the Canadian Kidney Cancer Information System and was presented at the American Society of Clinical Oncology (ASCO) 2019 annual meeting in Chicago earlier this week. During the study, patient outcomes and safety data were collected from patients who underwent active surveillance and compared to those who received immediate systemic treatment. […]

read more

ASCO GU 2019: Questions and lessons moving forward from CARMENA: A medical oncologist’s perspective

The following paper was presented at the American Society for Clinical Oncology (ASCO) genitourinary (GU) conference in San Francisco in February 2019. Cytoreductive nephrectomy (CN) is defined as the surgical removal of the primary renal cell carcinoma (RCC) tumour before starting systemic therapy. The following paper from medical oncologist Dr Lauren Harshman, Dana-Farber Cancer Institute, Boston, USA, suggests that this is an […]

read more
Showing all 5 results